Biomarker qualification in Barrett s oesophagus

一种称为腺癌的食道癌或食道癌在西方世界迅速增加。大多数患者直到出现吞咽困难才寻求医疗照顾，到那时癌症通常已经晚期，5年生存率为20%。但是，如果早期发现癌症，那么存活率可以提高到80%。这些癌症通常是一种叫做巴雷特的疾病的并发症。食管狭窄。然而，大多数人在人口与巴雷特？食道不会发展成癌症。因此，需要进行研究以确定食管癌风险最大的患者。在这项资助中，我们正在测试一些有前途的分子工具，看看它们是否可以使用来自北方爱尔兰巴雷特Oeospagus注册的大型临床活检资源来预测癌症进展。如果我们能找到一种预测癌症发展的分子检测方法，这将防止许多巴雷特食管癌患者进行不必要的内窥镜检查，并使我们能够将资源用于高危患者。

A type of oesophageal or gullet cancer, called adenocarcinoma, is rapidly increasing in the western world. Most patients do not seek medical attention until they develop swallowing difficulties and by then the cancer is usually advanced with a 5-year survival of 20%. However, if the cancer is detected early then the survival rate can be improved to 80%. These cancers usually develop as a complication of a condition called Barrett?s oesophagus. However, most people in the population with Barrett?s oesophagus will not develop cancer. Therefore research is needed to identify the patients at greatest risk for oesophageal cancer. In this grant we are testing some promising molecular tools to see whether they can predict cancer progression using a large clinical biopsy resource from the Northern Ireland Barrett s Oeospagus Register. If we could find a molecular test that predicted cancer development this would prevent many patients with Barrett s oeosphagus having unecessary endoscopy examinations and enable us to target resources to patients at highest risk.